Navigation Links
Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
Date:6/27/2011

was observed in the incidence of withdrawal from the study by any treatment group (placebo and the two arms).

Vaughan Clift, MD, Chief Regulatory Officer of Ampio, clarified that …"Statistical analysis of the IELT results is complex. The patients' IELT distribution is positively skewed (non-normal distribution) and requires specific statistical tests and reporting of results. For example, reporting the average (mean) IELT is an inappropriate estimator of effect size. The median or geometric mean are both generally considered to be more acceptable. Most published studies on PE report either the mean IELT or the geometric mean IELT. We chose to report the medians because a median makes no assumption about the underlying distribution. For the purpose of comparison with other studies on Tramadol and dapoxetine (Priligy®), we also report the mean and the geometric mean of our results. A more recent evidence based definition was published by the International Society for Sexual Medicine (ISSM) in 2010 that defines lifelong PE as: "Ejaculation which always or nearly always occurs prior to or within one minute of vaginal penetration". Over 50% (314 patients) of the patients included in our study met the new clinical criteria."

Don Wingerter, Ampio's CEO noted that ..." We are very pleased with the results of this phase III clinical study which demonstrated both efficacy and no safety concerns for Zertane™ in treating PE.  We are aggressively pursuing regulatory approval for Zertane™ in Europe and are in discussions with potential distribution partners in Europe and Asia.  Equally important, our intellectual property that protects our commercialization of Zertane™ also encompasses combination products which combine Zertane™ with erectile dysfunction drugs (PDE5 inhibitors and others), so we believe our franchise in the clinical field of sexual dysfunction will be expanded."

References

<
'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ampio Pharmaceuticals Set to Join Russell 3000 Index
2. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
3. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
4. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
5. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
6. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
7. Ampio Pharmaceuticals, Inc. Announces Appointment of New Chief Financial Officer to be Effective April 4, 2011
8. Kaiser Permanente Recognized as a J.D. Power 2011 Customer Service Champion
9. CHAMPION Study Published in The Lancet
10. Champions CFO Resigns
11. Champions Biotechnology Awarded $1.46 million in Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
(Date:7/9/2014)... Perelman School of Medicine at the University of Pennsylvania ... received an $8 million grant from the National Cancer ... therapy (PDT) in patients with malignant pleural mesothelioma, a ... itself in the lining of the lungs and is ... will fund a clinical trial and additional studies looking ...
(Date:7/9/2014)... heretofore hidden ways that cells are regulated, scientists at ... cancer cells more likely to metastasize. , What,s more, ... by blocking two other proteins that are normally linked ... processes could have unexpected ties. , The study, ... Nature , points to the possibility of new cancer ...
(Date:7/9/2014)... paint a relatively optimistic picture of women,s chances of ... to the chest wall or skin, but not beyond. ... of size and whether they have involved lymph nodes, ... "locally advanced" tumors, suggesting that they are a relatively ... advanced breast cancers of this and other types account ...
(Date:7/9/2014)... Researchers from The Miriam Hospital have found that ... are also depressed have difficulty sticking to a ... true for women, and screening and brief treatment ... treatment. The study and its findings are published ... , Chronic obstructive pulmonary disease is a common ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2
... Dec. 29 (HealthDay News) --,Concentrating on music can provide ... significant anxiety, according to a new study. Researchers ... the effectiveness of music as a pain reliever on ... a melody so they could identify the tones that ...
... HealthDay Reporter , THURSDAY, Dec. 29 (HealthDay News) -- ... crushing depression and crippling anxiety to powerful delusions and hallucinations ... the imagined. And if that weren,t enough, they also ... world perceives their inner struggle. Stigma associated with ...
... 29 (HealthDay News) -- In some cases, memory loss among ... research suggests. Such strokes, which may not cause any ... and are found in roughly 25 percent of older adults, ... study of memory loss in the elderly is that it ...
... HealthDay Reporter , WEDNESDAY, Dec. 28 (HealthDay News) -- ... lengthen progression-free survival by about four months for women with ... Avastin (bevacizumab) will make a difference in overall survival. One ... a difference in overall survival between two treatment groups. ...
... West Orange, NJ. December 28, 2011. The 2011 revision ... Spinal Cord Injury (ISNCSCI) was published in the November ... Medicine . The accompanying reference article by Steven Kirshblum ... Both are available for free download via http://www.ingentaconnect.com/content/maney/scm ...
... 2011) Treating ovarian cancer with the drug bevacizumab ("Avastin") ... results of an international clinical trial co-led by Drs. Amit ... and Timothy Perren, St James,s Institute of Oncology, Leeds, UK. ... England Journal of Medicine, report that the drug halted ...
Cached Medicine News:Health News:Even Today, the Stigma of Mental Illness Won't Fade 2Health News:Even Today, the Stigma of Mental Illness Won't Fade 3Health News:'Silent Strokes' Linked to Memory Loss in Elderly: Study 2Health News:Avastin May Help Some With Ovarian Cancer: Studies 2Health News:Avastin May Help Some With Ovarian Cancer: Studies 3Health News:Avastin May Help Some With Ovarian Cancer: Studies 4Health News:JSCM publishes revised International Standards for Neurological Classification of Spinal Cord Injury 2Health News:Ovarian cancer study proves drug delays disease progression, may improve survival 2
... have a direct thermal print surface ... HF-I transponder. When processed through a ... other graphics may be printed at ... programmed to the RFID transponder. Please ...
... The Radianse single-use active-RFID ... and convenience of medical consumables ... of Radianse reusable active-RFID tags. ... patient's ID wrist band, fit ...
... Techno THERM RFID labels are carefully ... materials and RFID antennas. SATO Techno ... and manufactured to ensure optimum performance ... SATO printer / encoders are available ...
PDC Smart® Wrist Tag provides read/write and data storage capabilities....
Medicine Products: